Skip to main content
NRXP
NASDAQ Life Sciences

NRx Pharmaceuticals Q2: FDA Ketamine Review Clears Major Hurdle, Cash Runway Extended to One Year

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.25
Mkt Cap
$137.155M
52W Low
$1.62
52W High
$5.055
52W Position info
101% above low
Off High info
36% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

NRXP has more than doubled off its 52-week low of $1.62.

Summary

NRx Pharmaceuticals reported Q2 2026 results with a $16.5 million net loss, but the key development is regulatory: the FDA completed its first-cycle review of the ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item—a manufacturer's attestation on the vial—has been submitted, positioning the company for potential 2026 approval and commercialization. The company has initiated commercial-scale manufacturing with 5 million doses of launch stock in process. Cash from the June $22.3 million offering is expected to fund operations for at least one year. Additional updates include DARPA selection for the SPARC-TMS Phase 2/3 trial with over $11.5 million in non-dilutive funding, advancement of the NRX-100 NDA using Real World Evidence from 65,000 patients, expansion of HOPE Therapeutics clinical sites, and appointment of a Chief Commercial Officer. This follows the 10-Q filed August 14th and adds operational detail on manufacturing readiness and regulatory progress. The conference call is scheduled for today at 4:30pm ET.

At the time of this announcement, NRXP was trading at $3.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137.2M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NRXP - Latest Insights

NRXP
Nov 17, 2026, 7:18 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.10
Real-time Price: $2.69 info
Change: +$0.590 (+28%) info
Market Cap: $120.129M info
NRXP
Oct 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $2.69 info
Change: -$0.2898 (-10%) info
Market Cap: $120.129M info
NRXP
Oct 15, 2026, 8:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $2.69 info
Change: +$0.140 (+5%) info
Market Cap: $120.129M info
NRXP
Oct 05, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.86
Real-time Price: $2.69 info
Change: -$0.170 (-6%) info
Market Cap: $120.129M info
NRXP
Sep 30, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.98
Real-time Price: $2.69 info
Change: -$0.2945 (-10%) info
Market Cap: $120.129M info